Valuation: Moderna, Inc.

Market Cap 25.06B 21.91B 20.22B 18.63B 35.12B 2,412B 35.9B 242B 94.59B 1,181B 94.1B 92.02B 4,068B P/E 2026 *
-7.29x
P/E 2027 * -13.3x
Enterprise Value 21.65B 18.93B 17.47B 16.09B 30.35B 2,084B 31.02B 209B 81.73B 1,021B 81.31B 79.52B 3,515B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 9.02x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-2.11%
1 week-19.25%
Current month-11.72%
1 month+11.59%
3 months+13.06%
6 months+47.79%
Current year+109.63%
1 week 61.06
Extreme 61.06
69.55
1 month 57.5
Extreme 57.5
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
02/07/26 Fiscal year

Chief Financial Officer

3,607 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%-19.25%+92.83%-49.06% 25.06B
-0.33%+1.31%+23.50%-5.82% 69.07B
+0.67%-4.28%+41.06%+201.69% 51.77B
+0.94%+39.60%+39.60%+39.60% 43.63B
+1.12%-1.76%-50.16%-52.75% 40.89B
-1.40%+3.56%+60.35%-26.15% 30.84B
+0.51%-1.07%+69.36%+89.85% 23.3B
-5.57%+3.01%+3.19%+174.11% 20.92B
-0.86%-3.55%+63.18%+127.04% 16.71B
+1.34%-9.75%+72.78%+346.65% 15.74B
Average -0.57%-2.50%+41.57%+84.52% 33.79B
Weighted average by Cap. -0.28%-1.80%+34.02%+61.82%

Financials

2026 *2027 *
Net sales 2.1B 1.83B 1.69B 1.56B 2.94B 202B 3B 20.21B 7.91B 98.76B 7.87B 7.69B 340B 2.55B 2.23B 2.06B 1.9B 3.58B 246B 3.66B 24.61B 9.63B 120B 9.58B 9.37B 414B
Net income -3.41B -2.98B -2.75B -2.53B -4.78B -328B -4.88B -32.89B -12.87B -161B -12.8B -12.52B -554B -1.85B -1.62B -1.49B -1.37B -2.59B -178B -2.65B -17.84B -6.98B -87.17B -6.94B -6.79B -300B
Net Debt -3.41B -2.98B -2.75B -2.53B -4.77B -328B -4.88B -32.85B -12.86B -161B -12.79B -12.51B -553B -2.05B -1.8B -1.66B -1.53B -2.88B -198B -2.94B -19.8B -7.75B -96.78B -7.71B -7.54B -333B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
17/07/26 US$61.82 -2.11% 4,539,781
16/07/26 US$63.15 -7.51% 5,593,100
15/07/26 US$68.28 +1.25% 3,427,825
14/07/26 US$67.44 +0.64% 5,812,332
13/07/26 US$67.01 -1.85% 8,521,959
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
61.82USD
Average target price
48.26USD
Spread / Average Target
-21.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock